Literature DB >> 357311

Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages.

I Amon, K Amon, H Hüller.   

Abstract

Metronidazole, a drug effective against certain protozoal and anaerobic infections, was given female patients with Trichomoniasis urogenitalis. Group I received twice daily 250 mg of metronidazole (supplied as 250 mg tablets Vagimid). Group II received in a single dose 1.0 g (4 tablets); and group III, 2.0 g (8 tablets). Serum and urine metronidazole levels were measured polarographically. Kinetic parameters were determined from the measured values of the concentration time curve by a computing program. An exact control of the therapeutic result was carried out. In all patients peak serum levels occurred within 1-3 hr and averaged 5.1 +/- 1.7 microgram/ml after 250 mg doses, 19.6 +/- 3.8 microgram/ml after 1.0 g doses and 40.6 +/- 9.3 microgram/ml after 2.0 g doses. About 35% of the administered dose was recovered in the urine in 12 hr and about 50% in 24 hr. Metronidazole shows protein binding of 10-20% equally in vivo and in vitro. Minimum trichomonacidic concentrations of nearly 1 microgram/ml were still present 12 hr after oral application of 250 mg metronidazole, and 24 hr to 36 hr, respectively after 1.0 g and 2.0 g daily doses. The cure rate was 100%. No serious side effects ocurred in any of the patients.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 357311

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  14 in total

1.  The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst.

Authors:  Robin E Pearce; Michael Cohen-Wolkowiez; Mario R Sampson; Gregory L Kearns
Journal:  Drug Metab Dispos       Date:  2013-06-27       Impact factor: 3.922

2.  A survey of pharmacokinetic data from pregnant women.

Authors:  A J Cummings
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of metronidazole.

Authors:  E D Ralph
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 4.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

6.  Influence of dose and route of administration on disposition of metronidazole and its major metabolites.

Authors:  S Loft; M Døssing; H E Poulsen; J Sonne; K L Olesen; K Simonsen; P B Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Metronidazole. A therapeutic review and update.

Authors:  C D Freeman; N E Klutman; K C Lamp
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.

Authors:  A H Lau; N P Lam; S C Piscitelli; L Wilkes; L H Danziger
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

9.  Managing trichomonal vaginitis refractory to conventional treatment with metronidazole.

Authors:  I H Ahmed-Jushuf; A E Murray; J McKeown
Journal:  Genitourin Med       Date:  1988-02

Review 10.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.